Bottom line
What is GMVAX's expense ratio?
GMVAX's expense ratio is 1.17%, or about $117 a year on every $10,000 invested. That is more expensive than 75% of mid-cap funds we track (median 0.88%). This share class also charges a front-end sales load of up to 5.5%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Dec 29, 2025
GMVAX fee table
| Net expense ratio | 1.17% |
|---|---|
| Gross expense ratio | 1.45% |
| Management fee | 0.8% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.4% |
| Fee waiver / reimbursement | -0.28% |
| Max front-end sales load | 5.5% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Dec 29, 2025
What GMVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| GMVAX | $663 | $957 | $1,273 | $2,167 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.17% expense ratio costs roughly $63,800 in lost growth, versus about $49,300 for the median mid-cap fund (0.88%).